2024 AHA/ACC Aspirin Management for Spine Surgery
According to the 2024 AHA/ACC guidelines, aspirin should generally be continued perioperatively for patients with coronary artery disease (CAD) undergoing noncardiac surgery, including spine procedures, unless the bleeding risk is prohibitive. 1
Primary Recommendation from 2024 Guidelines
The 2024 AHA/ACC perioperative guidelines provide a nuanced, risk-stratified approach rather than a blanket discontinuation period:
For Patients WITH Prior PCI (Stents):
- Continue aspirin (75-100 mg) perioperatively if possible to reduce cardiac events (Class 1, Level B-R) 1
- This applies even when other antiplatelet agents must be stopped
- The guideline explicitly states aspirin continuation is recommended to minimize major adverse cardiac events (MACE)
For Patients WITHOUT Prior PCI:
- May continue aspirin when cardiac risk outweighs bleeding risk (Class 2b, Level B-R) 1
- Routine initiation of aspirin is NOT beneficial for primary prevention (Class 3, Level B-R) 1
Critical Decision Framework
The 2024 guidelines emphasize that management should be determined by a multidisciplinary team weighing bleeding risk, thrombosis risk, and consequences of delayed surgery (Class 1, Level B-NR) 1. This is particularly relevant for spine surgery, which carries high bleeding risk.
When Aspirin Discontinuation IS Considered:
If aspirin must be stopped for high-bleeding-risk spine surgery:
The 2022 CHEST guidelines (which complement the AHA/ACC recommendations) suggest:
- Stop aspirin ≤7 days before surgery (not 7-10 days) for elective procedures requiring interruption 2
- This represents a shorter discontinuation window than older recommendations
The 2024 AHA/ACC guidelines do not specify exact discontinuation timing, instead prioritizing continuation whenever feasible 1.
Special Populations Requiring Aspirin Continuation
Aspirin should be continued through surgery in these high-risk scenarios:
Recent stent placement:
Secondary prevention patients:
- History of MI, stroke, or established CAD
- The 2012 AHA/ACC transplant statement noted aspirin should be continued if possible and restarted quickly if stopped 3
Practical Algorithm for Spine Surgery
Step 1: Identify indication for aspirin
- Primary prevention (no CAD/stroke) → May stop if needed
- Secondary prevention (prior MI/stroke/stent) → Strong preference to continue
Step 2: Assess bleeding risk of specific spine procedure
- Intracranial/spinal cord surgery = highest risk
- Multi-level fusion = high risk
- Single-level decompression = moderate risk
Step 3: Timing decision
- If continuing aspirin: Use 75-100 mg daily dose 1
- If stopping aspirin:
Step 4: Coordinate with cardiology
- Mandatory for patients with stents placed within 12 months 1
- Recommended for all secondary prevention patients
Important Caveats
The 2024 guidelines represent a paradigm shift from older recommendations that routinely stopped aspirin 7-10 days preoperatively. The current evidence-based approach prioritizes:
- Continuation over discontinuation when possible 1
- Shorter discontinuation periods (≤7 days, not 7-10 days) when necessary 2
- Individualized risk assessment rather than blanket protocols 1
Common pitfall: Older literature and some surgical practices still recommend 7-10 day discontinuation 4, 5. However, the most recent high-quality guidelines (2024 AHA/ACC and 2022 CHEST) support shorter interruption periods or continuation 1, 2.
For spine surgery specifically: While research suggests increased bleeding with aspirin continuation 4, 6, the 2024 guidelines prioritize cardiac risk reduction. A 2023 Delphi consensus of spine surgeons recommended stopping aspirin 7 days preoperatively 7, which aligns with the ≤7 day recommendation from CHEST guidelines 2 but conflicts with the AHA/ACC preference for continuation 1.
Postoperative Management
- Resume aspirin within 24 hours after surgery when hemostasis is adequate 2
- Earlier resumption (within 24 hours) preferred over delayed resumption 2
- For secondary prevention patients, total cessation duration should be <7-10 days to minimize thrombotic risk 6
The key principle: In 2024, the default is aspirin continuation unless bleeding risk clearly outweighs cardiac risk, with discontinuation periods shortened to ≤7 days when necessary.